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Abstract Cerenkov luminescence imaging (CLI) is a
novel molecular optical imaging technique based on the
detection of optical Cerenkov photons emitted by positron
emission tomography (PET) imaging agents. The ability to
use clinically approved tumour-targeted tracers in combi-
nation with small-sized imaging equipment makes CLI a
particularly interesting technique for image-guided cancer
surgery. The past few years have witnessed a rapid increase
in proof-of-concept preclinical studies in this field, and
several clinical trials are currently underway. This article
provides an overview of the basic principles of Cerenkov
radiation and outlines the challenges of CLI-guided surgery
for clinical use. The preclinical and clinical trial literature
is examined including applications focussed on image-
guided lymph node detection and Cerenkov luminescence
endoscopy, and the ongoing clinical studies and techno-
logical developments are highlighted. By intraoperatively
guiding the oncosurgeon towards more accurate and com-
plete resections, CLI has the potential to transform current
surgical practice, and improve oncological and cosmetic
outcomes for patients.
Keywords Cerenkov luminescence imaging  Image-
guided surgery  Cerenkov luminescence endoscopy 
Tumour margins  Lymph nodes
Introduction
Cancer surgery
The International Agency for Research on Cancer (IARC)
reports that 14.1 million new cancer cases were diagnosed
in 2012 worldwide, with 8.2 million cancer-related deaths.
By 2030, these figures will grow to 21.7 million new cases
and 13 million deaths, simply due to population growth and
ageing [2]. Of the estimated 21.7 million global new cancer
patients in 2030, 17.3 million, or approximately 80 %, will
need surgery as the main form of treatment [3].
For cancer surgery to have curative intent, complete
tumour resection (i.e. excision of all cancer tissue with no
residual loco-regional disease) is mandatory. To achieve
this, surgeons try to identify a tumour’s extent, and aim to
excise the lesion with a surrounding margin of healthy
tissue. In an effort to minimise functional loss and/or
cosmetic impairment, the goal is to remove the least pos-
sible amount of healthy tissue without compromising
oncological safety [4].
Palpation and visual inspection—combined with a sur-
geon’s experience and judgement—are currently the only
widely available ‘modalities’ to guide resection. These are
frequently inaccurate at discriminating between malignant
and normal tissue, resulting in positive tumour margin rates
of up to 50 % in some cancers [5–7]. Positive margins are
associated with a higher risk of local recurrence and poor
prognosis [8–11]. Adjuvant treatments such as radiother-
apy, hormone therapy or chemotherapy, and repeat opera-
tions to excise residual disease are often indicated to reduce
the likelihood of local recurrence, but these treatments can
impact on quality of life by causing significant physical and
emotional distress, and suboptimal cosmetic outcome [12,
13].
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With the above in mind, continuing efforts have been
made to assist surgeons in the process of determining
which tissue needs to be excised during cancer surgery.
Currently used clinical techniques include ultrasonography,
specimen radiography, and intraoperative histology and
cytology techniques. Although all of these techniques are
used to varying degrees in cancer surgery, none has quite
solved the Goldilocks problem of margins, due to limita-
tions in sensitivity, specificity, accuracy, or costs [14, 15].
Cerenkov luminescence imaging
Cerenkov luminescence imaging (CLI) is a novel imaging
modality that has great potential for image-guided surgery
in general, and the issue of surgical margins in particular.
CLI is based on the detection of Cerenkov photons emitted
by positron emission tomography (PET) imaging agents.
Cerenkov photons are emitted by a charged particle
(positron or electron) when travelling through a dielectric
medium at a velocity greater than the velocity of light in
that medium. The Cerenkov phenomenon seems to have
been first observed by Marie Curie in the late 19th century.
In her biography, she describes observing a pale blue glow
from the radium-containing bottles in her laboratory. The
first person to systematically describe Cerenkov radiation
was Pavel Cerenkov, and together with Il’ja Mikhailovic
Frank and Igor Yevgenyevich Tamm who developed the
theoretical framework, they won the Nobel Prize in Physics
in 1958 for their contribution to the discovery of the Cer-
enkov effect. In the lay mind, Cerenkov radiation is known
as the blue glow in the cooling water basins that surround
nuclear reactors.
By detecting the optical photons from PET imaging
tracers, CLI combines optical and molecular imaging.
Robertson et al. were the first who demonstrated that CLI
with PET agents can be used to image cancer in vivo [16],
and since then, this technology has rapidly emerged in the
field of biomedical imaging. In recent years, several review
papers have outlined the various applications of CLI
including its use in Cerenkov luminescence imaging
dosimetry (CLID), radionuclide therapy monitoring,
tumour response monitoring and photoactivation therapy
[17–21]. An in-depth explanation of the complex physics
underlying Cerenkov radiation and CLI has also been
reported [22, 23].
The aim of this review paper is to provide an overview
on the use of CLI for image-guided interventions with a
specific focus on image-guided cancer surgery. The first
section of this paper outlines the characteristics of Cer-
enkov radiation and CLI. Rather than describing these
characteristics using complex physical equations as already
done by others, this review provides a simplified explana-
tion with an emphasis on the features that are relevant to
image-guided surgery. The second section of this paper
contains an overview of the published work in this field to
date, and the last section will highlight the ongoing clinical
studies and technological developments.
Cerenkov radiation: the basics
Cerenkov radiation is produced when a charged particle
travels through a dielectric medium, i.e. a medium that can
be polarised by an electric field, with a speed faster than the
speed of light in that medium [24]. When propagating, the
charged particle (a positively charged positron or nega-
tively charged electron) induces a local polarisation by
displacing the positive and negative charges of the atoms in
the medium (Fig. 1). In a situation where the particle’s
velocity does not exceed the speed of light in that medium,
the polarisation field surrounding the particle is perfectly
symmetrical, and there is no electric field at larger dis-
tances. The net result is that no Cerenkov radiation is
emitted. When the particle’s speed exceeds the speed of
light, however, the polarisation becomes asymmetrical
along the track of the particle, resulting in a dipole electric
field at larger distances from the particle. As the particle
passes the electrons of the atoms return to their ground
state, thereby emitting the transferred energy as optical
photons that are known as Cerenkov radiation. Thus,
Cerenkov radiation is produced as secondary emission; it is
not the charged particle generating light, but the medium as
a reaction to the particle.
For Cerenkov radiation to be emitted, the charged
particle needs to exceed a certain energy threshold. This
threshold is expressed by v  c=g, where m is the charged
particle’s velocity, c is the speed of light in vacuum, and g
is the refraction index of the medium. From this expres-
sion, it becomes clear that the Cerenkov threshold is
related to the refractive index of the medium. Using the
relationship between the velocity of the particle and its
energy as described by equations 2 and 3 in Gill et al., it is
found that in water with a refractive index of 1.33, the
threshold is 0.264 MeV [25]. In soft tissues, the refractive
index typically ranges from 1.36 to 1.40, resulting in a
threshold for the production of Cerenkov radiation of
approximately 0.219–0.250 MeV. These thresholds are
lower than the beta particle energies from radionuclides
used in PET, and these radionuclides thus emit Cerenkov
radiation in both water and tissue [26]. As the charged
particle travels through the medium, it loses energy due to
interactive processes with its surroundings including
354 Clin Transl Imaging (2016) 4:353–366
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absorption and scattering, and eventually, its energy falls
below the threshold, and Cerenkov light is no longer
produced. For the much heavier alpha particles, the Cer-
enkov threshold in water and tissue is 1926 and
1673 MeV, respectively [27]. Although none of the
energies from existing alpha-emitting radionuclides come
near this threshold (typical alpha particle energies range
between 3 and 7 MeV), studies have shown emission of
Cerenkov photons by alpha emitters [27–29]. There are
two explanations for this observation, depending on the
type of radionuclide: either photons arise from the short-
lived beta-emitting daughter radionuclides of some alpha
emitters (e.g. Actinium-225), or they are produced by
electrons that arise from Compton scattered high-energy
gamma photons. Regardless of the mechanism, Cerenkov
radiation from alpha emitters is, thus, produced indirectly
by secondary beta particles. The pure gamma-emitter
Technetium-99 m (99mTc) is also able to produce optical
photons as shown by several groups [30–32]. Although
the mechanism of this optical emission is not yet fully
understood, it is assumed to be from OH radicals that are
excited by the low energy Compton electrons [30] or from
gamma excitation of the luminophores that are present in
99mTc based tracers (e.g. the amino acids in 99mTc-
macroaggregates albumin) [32]. This form of lumines-
cence is known as radioluminescence and differs from
Cerenkov radiation; it has a different wavelength spec-
trum, and its signal intensity is lower in tissue [33]. The
latter may provide additional challenges for its use in
image-guided interventions. In the remainder of this
review, our focus will, therefore, solely be on Cerenkov
radiation.
The number of Cerenkov photons N emitted per distance
travelled x can be calculated using equation 1, which is
derived from the Frank–Tamm equation [25]:
dN
dx
¼ 2pa 1 1
b2g2
  Zk2
k1
1
k2
dk
Here, a is the fine structure constant (1/137), b is the ratio
between particle’s velocity and the speed of light in vac-
uum (m/c), and the integral is over the interval k1 to k2.
From this equation, it follows that the intensity of the
Cerenkov radiation depends on a particle’s velocity, and
thus, its energy. Fluorine-18 (18F), the most commonly
used radionuclide in PET imaging, has an average and
maximum b-energy of 250 and 633 keV, respectively. As a
result, only 47 % of the decays produce a positron that
exceeds the energy threshold for production of Cerenkov
radiation in water [22]. Yttrium-90 (90Y), a radionuclide
often used in radiation therapy, has a much higher average
and maximum b-energy of 934 keV and 2.28 MeV,
respectively, and 90 % of its produced electrons are above
the Cerenkov threshold in water. Gill et al. recently studied
47 radionuclides widely used in nuclear medicine, and used
Monte Carlo simulations to quantify the expected Cer-
enkov light yield (photons/decay) for each radionuclide in
tissue (g = 1.4) [25]. They found that 18F emits 2.58
photons per decay in tissue; approximately 23 times less
than the 58.5 photons per decay emitted by 90Y. The light
yield from some commonly used radionuclides in order
from high to low is shown in Table 1. Although it is
important to realise that the reported light yields do not
take into account the wavelength-dependent absorption and
Fig. 1 A charged particle, in this case an electron, passing through a
dielectric medium with a a particle speed (m) lower than speed of light
in that medium (c/g), b a particle speed larger than speed of light in
that medium. The condition such that Cerenkov luminescence is
produced along the particle’s track requires m C c/g
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wavelength-dependent scattering that would occur in
human tissue—this would reduce the number of
detectable photons—it is clear that the signal intensity of
CLI can be improved significantly using higher-energetic
isotopes. However, even with the use of such isotopes, the
Cerenkov light yield from a single radioactive decay pro-
cess is low in comparison to, for example, the light yield
from a single fluorescent molecule. Fluorescein and Indo-
cyanine green (ICG), fluorophores used in fluorescence
image-guided surgery, emit roughly three orders of mag-
nitude more photons [34]. This low light yield requires
strict control of the light environment to obtain a sufficient
signal-to-background ratio (SBR) when using CLI in an
intraoperative setting as explained below.
Another characteristic of Cerenkov light is its broad
emission spectrum that ranges from approximately 350 to
900 nm [16]. The light intensity is inversely proportional to
the square of the wavelength (1/k2). This is why Cerenkov
radiation is strongest towards the blue end of the visible
spectrum, and hence why Cerenkov radiation appears blue.
The fundamental resolution of Cerenkov radiation is
determined by the distance over which a b-particle emits
light. It was found that for 90Y and 18F, this distance is
approximately 2 and 0.3 mm, respectively [22]. This shows
that lower-energetic tracers have a better physical resolu-
tion limit, but the downside is a lower light yield, and thus,
sensitivity.
Characteristics of CLI from an image-guided
surgery perspective
CLI images can be acquired by detecting the Cerenkov
light from PET tracers using ultra-high-sensitivity optical
cameras such as electron-multiplying charge-coupled
device (EMCCD) cameras. The CLI image can be analysed
semiquantitatively in photon radiance. CLI and PET are
directly correlated due to both techniques measuring the
photons produced by positron-emitting radiopharmaceuti-
cals; PET measures the annihilation photons, and CLI
measures the Cerenkov photons. Several studies have
shown a strong correlation between CLI and PET for dif-
ferent radiopharmaceuticals in vitro, ex vivo and in vivo,
thus demonstrating the feasibility of CLI for molecular
Table 1 Relevant characteristics of Cerenkov radiation and CLI for image-guided cancer surgery
Cerenkov radiation definition Optical radiation emitted by charged particles when travelling through a dielectric
medium with a speed larger than the speed of light in that medium
Threshold energy for Cerenkov radiation emission [25] Water (g = 1.33): 0.264 MeV
Biological tissue (g = 1.36–1.40): 0.219–0.250 MeV
Cerenkov radiation is emitted by b?, b-, and a-emitting radionuclides
Cerenkov intensity from radionuclides most commonly
used in clinic in order from high to low [25]
90Y[ 68Ga[ 15O[ 124I[ 11C[ 89Zr[ 18F[ 131I[ 64Cu
Cerenkov radiation spectrum [16] 350–900 nm
Fundamental resolution [22] 0.3–2.00 mm
Camera requirements for Cerenkov radiation detection High-sensitivity optical cameras with single-photon detection capability
Typical penetration depth in tissue [70] *1–2 cm
Typical CLI acquisition times 1–5 min
Types of images acquired with CLI Photographic image: anatomical information
Functional image: information on the uptake and location of the
radiopharmaceutical
Advantages of CLI for image-guided cancer surgery Ability to use clinically approved tumour-targeted radiopharmaceuticals
Potential for multi-modality imaging with the same tracer: preoperative imaging
with gamma-camera, PET or SPECT, intraoperative imaging using CLI ± beta-
probe or gamma-probe
Small form factor of CLI equipment allowing implementation of CLI technology in
intraoperative specimen chamber, flexible endoscope and rigid laparoscope
External excitation source not required: less tissue autofluorescence
Challenges of CLI for image-guided cancer surgery Faint signal
Light-tight imaging conditions required
Radiation dose to patient and staff
Strict regulations for use of radiotracers
Complex logistics that requires close multi-disciplinary team work
356 Clin Transl Imaging (2016) 4:353–366
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imaging of living subjects. An overview of the published
literature on the correlation between CLI and PET is pro-
vided in Table 2. Results on the correlation between CLI
and radiotracer activity are also included in this table.
There are several reasons why CLI has sparked so much
interest in the field of biomedical imaging, and why it is a
promising technology to guide surgical resection. Firstly,
CLI images can be acquired with clinically approved
tumour-targeted radiopharmaceuticals that have been used
for over two decades in molecular medical imaging [26].
This provides great potential for rapid translation of CLI
into clinical practice. Especially, the possibility to use the
most commonly used PET radiopharmaceutical 2-deoxy-2-
(18F)fluoro-D-glucose (abbreviated 18F-FDG) facilitates
wide clinical adoption of CLI, as this is a versatile tracer
that can be used in several solid cancers, including lung
cancer, colorectal cancer, melanoma, head and neck can-
cer, breast cancer and oesophageal cancer [35].
The ability to use clinically approved tumour-specific
tracers is an important advantage over conventional optical
imaging techniques, such as targeted fluorescence imaging,
as to date, there are no tumour-specific fluorescent tracers
that have been approved by the FDA or EMA [36]. Targeted
fluorescence imaging faces a significant commercial hurdle
for clinical adoption, because the process of obtaining reg-
ulatory and reimbursement approval is costly and lengthy
[37], while the revenue of imaging agents is often low
compared to therapeutic agents, which makes it a signifi-
cantly less interesting investment for industry [38, 39].
In addition to the already approved PET tracers, a sig-
nificant number of new tracers are being developed for
market approval including 68Ga-PSMA, 68Ga-DOTATOC,
18F-NaF, 18F-Choline, and 18F-FDOPA [40].
The ability to use the same tracer for both CLI and PET
or SPECT enables dual-modality molecular imaging. PET
and SPECT provide preoperative information on the loca-
tion and extent of the tumour, while CLI can be used as an
intraoperative adjunct to aid lesion identification and guide
surgical resection. The use of the same tracer ensures
visualisation of the same structures and facilitates a more
accurate comparison between modalities. Depending on the
patient pathway and half-life of the tracer, preoperative and
intraoperative imaging could be performed using only one
tracer injection, or by reinjecting the tracer. By capturing a
white-light image with a standard camera at the time of
CLI image acquisition, the functional information from the
CLI image can be combined with the anatomical and
structural information from the photograph, thereby pro-
viding the surgeon unprecedented information on the nat-
ure, location, and extent of the cancerous tissue.
Beta-emitting radiopharmaceuticals can also be detected
by a beta probe or gamma probe [41–43], so these tools
Table 2 Literature overview on the correlation of CLI and PET
CLI parameter PET parameter Correlation between CLI and PET Radiopharmaceutical In vivo, in vitro, ex vivo Refs.
Radiance %ID/g R2 = 0.93, 0.95, 0.93, 0.89 18F-FDG In vivo [71]
Radiance %ID/g R2 = 0.97 18F-FDG In vivo [26]
Radiance Activity R2 = 0.95 18F-FDG In vivo [72]
Radiance Activity R2 = 0.98 18F-FDG In vivo [73]
Radiance PET± P = 0.02 18F-FDG In vivo [61]
Radiance %ID/cm3 R2 = 0.83 18F-FDG In vivo [74]
Radiance %ID R2 = 0.82 18F-FDG In vivo [74]
Radiant vol. Glycolytic vol. R2 = 0.99 18F-FDG In vivo [74]
Radiance Activity R2 = 0.99 18F In vitro [75]
Radiance Activity R2 = 0.97 18F-FDG In vitro [64]
Radiance Activity conc. R2 = 0.99 18F-FDG In vitro [61]
Radiance Activity R2 = 0.97 18F-FDG Ex vivo [72]
Intensity Activity conc. R2 = 0.98 68Ga In vitro [76]
Intensity Activity conc. R2 = 0.99 68Ga In vivo [76]
Radiance %ID/g R = 0.89 89Zr-trastuzumab In vivo [1]
Radiance %ID/g R = 0.98 89Zr-J591 In vitro [28]
Radiance Activity conc. R = 0.98 89Zr-J591 In vitro [28]
Radiance %ID/g R2 = 0.85 89Zr-rituximab In vivo [77]
Radiance Activity R2 = 0.98 Na-131I In vitro [68]
Radiance Activity R2 = 0.99 131I-NGR In vitro [78]
Radiance %IA/g R2 = 0.94, 0.98 90Y-DOTA-AR In vivo [79]
Radiance %IA/g R2 = 0.91, 0.99 90Y-DOTA-AR Ex vivo [79]
Clin Transl Imaging (2016) 4:353–366 357
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could potentially be used in addition to CLI-guided surgery
to overcome the limited penetration depth of CLI as a
result of absorption and scattering, thereby further ensuring
successful tumour resection.
Another advantage of CLI is that the optical imaging
systems required to acquire an image can be small in
dimension or use fibre-optics or laparoscopic capabilities.
Unlike a PET system, this provides the ability to use CLI in
an operating theatre or in endoscopy equipment, and exam-
ples of such applications are provided in the next section.
CLI faces a number of challenges for routine clinical
adoption. As mentioned earlier, Cerenkov luminescence is
very faint due to the small number of optical Cerenkov pho-
tons emitted by charged particles. In biological applications,
the signal intensity is further reduced by strong tissue atten-
uation from chromophores like (oxy)haemoglobin and light
scattering which is more pronounced in the 400–650 nm
range [44, 45]. Consequently, the acquisition time required to
obtain high-resolution imageswith a sufficient signal-to-noise
ratio (SNR) is longer than with conventional optical imaging.
Typical imaging times in preclinical and clinical CLI studies
range from 1 to 5 min (Table 3). Although these images are
not available in ‘real-time’, these acquisition times are con-
sidered feasible for most intraoperative applications. How-
ever, when imaging with handheld devices (e.g. endoscopes),
it is essential that during image acquisition, the device is not
moved as this causes blurring of the image resulting in a
reduced image quality. In an in vivo environment, this may
prove especially difficult due to bowel activity and breathing
artefacts, and motion-correction algorithmsmay be needed to
correct for this.
The weak light intensity also requires a light-tight
environment as any leakage of ambient light will over-
whelm the CLI signal. Since Cerenkov radiation is stron-
gest in the visible wavelengths, it cannot be spectrally
separated from the much brighter ambient lights currently
used in operating theatres. Control of the light environment
is, therefore, currently achieved by imaging in a light-tight
specimen chamber or room with light-sealed doors, or in
anatomical areas that provide natural darkness (e.g. gas-
trointestinal tract).
An often mentioned limitation of optical imaging, in
general, is the limited light penetration depth, and thereby,
the inability to image deep located tissue. This was nicely
illustrated by Chin et al. who calculated the reduction in
signal intensity from one 18F-isotope and one ICG mole-
cule in 1 mm of tissue, and found a reduction in signal
intensity of 77 and 39 %, respectively [34]. Because Cer-
enkov light is ‘blue-weighted’ and tissue absorption and
scattering are significantly increased for these wavelengths,
CLI is mainly applicable for imaging superficially located
tissue.
Table 3 Overview of published studies on CLI-guided surgery
Preclinical
or clinical
Indication Tumour type Tracer Dose CLI device Acquisition
time
Refs.
Preclinical CLI-guided
tumour
resection
HER2? breast
cancer
89Zr-DFO-
trastuzumab
4 MBq Ivis optical imager 2–5 min [1]
Preclinical CLI-guided
tumour
resection
Glioblastoma 68Ga-
3PRGD2
3.7 MBq Ivis optical imager 1–5 min [80]
Preclinical Cerenkov
luminescence
endoscopy
Brain glioma 18F-FDG 37 MBq Custom-build flexible fibre
endoscope light-tight box
5 min [62]
Preclinical Cerenkov
luminescence
endoscopy
Glioblastoma 90Y-PRGD2,
18F-FP-
PRGD2
8.1 MBq,
33 MBq
Custom-build flexible fibre
endoscope light-tight box
6 min [81]
Preclinical Cerenkov
luminescence
endoscopy
Colon cancer 18F-FDG 24 MBq Clinically approved rigid laparoscope
coupled to EMCCD camera in light-
tight box
5 min [82]
Clinical Cerenkov
luminescence
endoscopy
Rectal cancer 18F-FDG 9.25 MBq/kg Clinically approved flexible fibre
endoscope coupled to EMCCD
camera
5 min [73]
Preclinical CLI-guided
lymph node
mapping
N/A 68Ga-
SPIONsa
5–10 MBq CCD camera positioned in light-tight
box
2–10 min [53]
Preclinical CLI-guided
lymph node
mapping
N/A 18F-FDG 1.2 MBq Ivis optical imager 2 min [52]
a Superparamagnetic iron oxide particles (SPIONs)
358 Clin Transl Imaging (2016) 4:353–366
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Due to the half-life dependency of radiotracers, the
window in which CLI imaging needs to be performed to
obtain a sufficient SNR and image quality is limited. Well-
designed logistics and close collaboration between nuclear
medicine, radiology and surgical departments are, there-
fore, a prerequisite for the successful implementation of
CLI in current clinical and surgical workstreams.
A challenge for CLI-guided surgery in particular is the
radiation exposure to patients and theatre staff from using
radiopharmaceuticals. For patients, the effective dose from
a 300 MBq 18F-FDG injection is approximately 6 mSv;
this is comparable to the radiation dose for a typical chest
CT scan [46] and much lower than the 20–2500 mSv
radiation exposure from diagnostic and interventional flu-
oroscopy procedures [47]. Staff that work in close prox-
imity of the patient during surgery are also exposed to
radiation. The received radiation dose is dependent on the
time between injection and the start of the interventional
procedure, as well as the duration of the procedure. Various
groups have published staff radiation doses from 18F-FDG-
guided cancer surgery procedures [48–50], and have shown
that the radiation dose received per procedure is generally
low. For example, for a 105 min procedure starting
approximately 1 h after injection of 370 MBq 18F-FDG,
the exposure to the surgeon was 42 lSv [48]. However,
depending on the national annual occupational dose limit
(50 mSv in the United States, and 20 mSv in most other
countries) and type of procedure, the number of procedures
an individual can perform per year without exceeding the
permissible limits for professional workers may be
restricted. Regardless of these limits, there are strict
requirements for the use of radioactivity in clinical prac-
tice. For example, routine staff monitoring is a requisite for
each institution that conducts radiotracer guided proce-
dures, strict regulations need to be followed with regards to
clinical waste disposal and handling of radioactive speci-
mens, and staff need to attend radiation safety training
prior to participation in any procedure involving radiation
[51]. These requirements could hinder adoption of radio-
guided surgical technologies, especially in small district
hospitals that do not have access to nuclear medicine or
radiation safety departments. The aforementioned charac-
teristics of Cerenkov radiation and CLI in light of image-
guided surgical applications are summarised in Table 1.
Applications of CLI for image-guided surgery
and ongoing clinical trials
After it was first described in 2009, CLI has gained sig-
nificant scientific interest. A search of Embase and Medline
performed on 28 December 2015 using the keywords
‘Cerenkov Luminescence Imaging’ provided a total of 103
and 59 articles, respectively. Despite the limitations men-
tioned in the previous section, various research groups have
been successful in using CLI for image-guided surgical
interventions. An overview of the results published to date
is provided in Table 3. The majority of this work is pre-
clinical, although one clinical study was also published
recently. In addition to the tumour types shown in Table 3,
CLI-guided surgery could also be applied to other super-
ficial malignancies where precision surgery is essential for
preserving organ function, such as neoplasms in the oral
cavity and genital tract. However, publications of CLI in
these malignancies have not yet emerged.
The published studies show the ability to perform CLI-
guided surgical excision of tumours using a variety of
radiopharmaceuticals and different CLI embodiments,
including standard IVIS optical imaging systems, custom-
build flexible fibre endoscope systems, and clinically
approved rigid laparoscope and flexible endoscope systems
coupled to EMCCD cameras. An example that nicely
illustrates CLI-guided tumour excision is shown in Fig. 2.
An important advantage of using CLI in an endoscopic
setting is that these make use of anatomical dark chambers,
so that there is no interference from external light sources.
Besides, this technology can also be implemented in other
types of endoscopes, such as a bronchoscope or hystero-
scope, and future applications of CLI could, for example,
focus on lung cancer, endometrial cancer and metastatic
lymph nodes in the abdomen, pelvis and thorax.
CLI has also been successfully used for lymph node
identification and image-guided lymph node excision using
18F-FDG and 68Ga-labelled superparamagnetic iron oxide
particles (SPIONs) [52, 53].
Another interesting application of CLI, although not
directly related to image-guided surgery, has been pub-
lished by Spinelli et al. [54]. They imaged the thyroid gland
of a patient treated for hyperthyroidism who received
550 MBq of Iodine-131 (131I). Using an EMCCD camera
positioned in a light-tight room, tracer uptake in the thyroid
could be visualised with a 2-min exposure time. This
application is of clinical interest as imaging the uptake of
beta-emitting radiopharmaceuticals could provide a rapid
and inexpensive alternative for monitoring radiation doses
given to superficial organs.
The successful applications of CLI for image-guided
cancer surgery have resulted in several clinical studies that
are currently ongoing to evaluate the feasibility of this
technique in different tumour types. At Guy’s Hospital
(London, UK), a first-in-woman pilot study evaluates
intraoperative CLI for measuring tumour resection margins
and lymph node status in 30 patients undergoing breast-
conserving surgery (BCS) (ClinicalTrials.gov identifier
NCT02037269). Patients receive an intravenous standard
of care PET dose of 5 MBq/kg 18F-FDG, and excised wide
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local excision (WLE) specimens and lymph nodes are
imaged within 1–3 h post-injection using an investigational
intraoperative CLI specimen camera (Lightpoint Medical
Ltd, UK) (Fig. 3). The investigational CLI camera consists
of a light-tight sample chamber, a radiation-shielded ther-
moelectrically-cooled EMCCD camera, and a f/0.95 lens.
The camera provides 8 9 8 cm field of view and 156 lm
intrinsic spatial resolution. Interim results show that ele-
vated radiances are detected in cancer compared to normal
breast tissue, and that the radiation exposure to surgical
staff is low [55, 56]. The results from comparing CLI
resection margin status and lymph node status to the gold-
standard, histopathology, are being prepared for publica-
tion at the time of writing. An example of a CLI image
from a WLE specimen that was scanned intraoperatively in
this clinical study is shown in Fig. 4. This image illustrates
that CLI provides high-resolution functional information
that allows surgeons to accurately assess tumour margins
during surgery.
To evaluate the effect of intraoperative 18F-FDG CLI
on reoperation rate and quality of life in BCS, a
randomised, controlled, multi-centre clinical study is
scheduled to commence in mid-2016 (ClinicalTrials.gov
identifier NCT02666079). This will run across an antici-
pated eight study sites in the UK and Germany, and use the
CE-marked LightPathTM Imaging System (Lightpoint
Medical Ltd, UK).
Another CLI study that is currently being conducted at
Guy’s Hospital and University College London Hospital
focusses on tumour margin evaluation in prostate cancer
(ClinicalTrials.gov identifier NCT02151097). Patients
undergoing a therapeutic radical prostatectomy receive a
370 MBq intravenous injection of 18F-Choline, and the
margins of the resected prostatectomy specimen are
imaged using the investigational intraoperative CLI cam-
era. The initial results show that intraoperative 18F-Choline
CLI is a feasible and low-risk procedure [57]. Elevated
radiances were present in all three primary tumours (tu-
mour-to-background ratio between 2.49 and 4.90), and CLI
imaging did not add additional time to surgery. The
assisting surgeon and scrub nurse received the highest body
dose; 110–180 and 40–80 lSv, respectively. Work is
Fig. 2 89Zr-DFO-trastuzumab CLI-guided tumour excision. a Empty
background image acquired prior to surgery. b Image acquired pre-
incision and c post-incision after removal of the skin. An elevated
tumour radiance is visible in the HER2/neu positive tumour (red
circle); 89Zr-DFO-trastuzumab is not taken up in the HER2/neu
negative tumour, and this tumour, therefore, does not display an
elevated radiance (blue circle). Note the increase in radiance due to a
reduction in tissue absorption and scattering after removal of the skin.
d Image of the surgical cavity after excision of the HER2/neu positive
tumour. An elevated radiance from the excised tumour specimen is
visible (red circle). No CLI signal is left at the excision site indicating
complete tumour resection. e Image of excised tumour alone. f Image
acquired straight after the surgical wound was closed with sutures.
This research was originally published in Molecular Imaging [1]
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currently being done to perform CLI imaging with the
Gallium-68 (68Ga) labelled prostate specific membrane
antigen (PSMA); a tracer that has strong advantages over
18F-Choline. PSMA is a cell surface target that is highly
expressed by nearly all prostate cancers, and 68Ga-PSMA
is, therefore, highly taken up in prostate cancer cells [58].
The Cerenkov radiance from 68Ga in tissue (g = 1.4) is
approximately 17 times higher compared to 18F, which
could facilitate a reduction in tracer dose, thereby lowering
the radiation exposure to theatre staff. The shorter 68Ga
half-life of 68 min means that contaminated surgical
instruments and surgical waste can be cleaned and disposed
much quicker. Another advantage is that besides imaging
the primary tumour, this tracer also holds promise for
visualising small lymph node metastases [59].
In addition to imaging resected WLE specimens ex vivo,
scanning the post-resection surgical cavity for residual
tumour that cannot be identified by visual inspection or
palpation could further aid achieving complete excision of
cancers. Detection of beta-radiation with handheld betas-
copes can identify small areas of malignant cells [60], and
clinical studies to test the combination of in vivo betascope
detection and ex vivo CLI will soon commence in gas-
trointestinal cancers (ClinicalTrials.gov identifier
NCT02446379) and breast cancer (ClinicalTrials.gov
identifier NCT02151071).
Another interesting application of CLI that is currently
being evaluated is the non-invasive detection of nodal
disease in a preoperative clinical setting (ClinicalTrials.gov
Identifier NCT01664936). In this observational study,
patients with lymphoma, leukaemia and metastatic lym-
phadenopathy scheduled to undergo standard clinical 18F-
FDG PET are included. CLI imaging is performed imme-
diately after the PET-scan in a dark room with a single-
photon sensitive camera positioned on a standard photog-
raphy tripod. The preliminary results of this study from
four patients (two lymphoma, one lung cancer and one
breast cancer) showed that metastatic lymph nodes in the
neck or axilla, located at 1.6 ± 0.5 cm under the skin, had
a statistically significant higher Cerenkov signal than
negative nodes (P = 0.02), and this finding strongly cor-
related with the results from PET [61]. Examples of patient
population that can benefit from accurate preoperative
identification of nodal disease are breast cancer patients
with involved lymph nodes. If positive lymph nodes are
identified preoperatively on CLI, their treatment could
convert from sentinel lymph node biopsy (SLNB) to
immediate axillary node clearance (ANC), thus preventing
the patient from undergoing an unnecessary surgical pro-
cedure. Alternatively, these patients may undergo neoad-
juvant chemotherapy followed by SLNB ± ANC.
Completion of this study will provide further insight in the
Fig. 3 Investigational intraoperative CLI imaging system used in
breast-conserving surgery trial. a Computer aided design (CAD)
rendering. The red object indicates the location of the tissue specimen
within the specimen chamber. b Schematic diagram showing: (1)
thermoelectrically-cooled EMCCD camera, (2) f/0.95 lens, (3) hinged
reflex mirror, (4) CMOS reference camera for anatomical imaging,
(5) specimen holder, (6) lead radiation shielding for EMCCD camera,
(7) focal zone, (8) fixed lens for reference camera, (9) filter wheel,
(10) LED RGB light array, (11) specimen chamber. The purple line
shows the optical paths for the EMCCD camera and the reference
camera as determined by the angle of the reflex mirror
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real value of preoperative CLI imaging in aiding surgical
and medical decision-making.
Future technical developments
CLI has only recently been introduced as a modality for
imaging biological tissue, and this technique is, therefore,
still in its infancy. In the last decade, advances in optical
imaging devices in the biophotonics field have progressed
rapidly with the development of highly sensitive, charge-
coupled detectors (CCD), and current technological
developments focus on further increasing the sensitivity of
this imaging technology. This would facilitate a reduction
in acquisition time, and a reduction in the administered
radiopharmaceutical dose.
Improvements in detection sensitivity can be achieved
using more specialised optics and more sensitive detectors.
For example, the Schott-75 glass used in the CLI prototype
device of Liu et al. transmits only 40 % of light at 500 nm,
and impurities in the glass scintillate gamma photons,
which increase background noise [62]. The use of fused
silica, which transmits further in the violet and ultraviolet
wavelengths and has fewer impurities, would significantly
improve detection sensitivity.
In non-invasive CLI imaging, improvements in sensi-
tivity may be obtained by using CCD cameras that are
optimised to detect Cerenkov radiation in the UV for sur-
face imaging, or in the near-infrared (NIR) for deep
imaging. Spinelli et al. showed in a theoretical analysis that
a CCD detector with a quantum efficiency peak in the NIR
range could enhance the number of detected Cerenkov
photons by 35 %, especially for Cerenkov source located
deeper inside the tissue [63].
As already described in the section ‘Cerenkov radia-
tion’, Cerenkov light is mainly weighted towards the
ultraviolet (UV) and blue part of the spectrum. The high
absorption and scattering of these frequencies in bio-
logical tissue hampers CLI detection and quantification.
To overcome these limitations, current work focusses on
shifting the CLI emission spectrum to NIR wavelengths
by ways of Cerenkov radiation energy transfer (CRET).
Different research groups have done this using fluores-
cent quantum dots (QDs) or other fluorophores, in vitro
and in vivo animal models [64–66]. The broad excitation
spectrum that matches the CR spectrum and the narrow
emission spectrum make QDs specifically favourable.
NIR wavelength light would enable the use of spectral
filters to reduce interference from external light source,
thus facilitating the use of CLI in the intraoperative
suite. However, as with targeted fluorescent probes,
nanoparticles have not yet received marked approval,
and these approaches can, therefore, not be used clini-
cally yet.
Another interesting development in the field of CLI is
the acquisition of three-dimensional (3D) images by means
of Cerenkov luminescence tomography (CLT). Different
reconstruction approaches have been proposed using multi-
view [67, 68] or multi-spectral [69] imaging methods, all
showing a good correlation in radiotracer distribution on
CLT and PET or SPECT, respectively. Although each
method is currently still limited in terms of acquisition time
or spatial resolution and has only been used preclinically,
the ability of CLT to provide 3D information on the in vivo
distribution of radiopharmaceuticals could provide a more
Fig. 4 Wide local excision specimen from a patient with a 22 mm,
grade 2, ER?/HER2- invasive lobular carcinoma. The specimen was
incised to expose the primary tumour and margins of excision, and
subsequently scanned with the investigational CLI camera.
a Cerenkov image, b white-light photograph (black and white)
overlaid with Cerenkov signal. An increased radiance from the
tumour is visible (white arrows); mean radiance is 544.0 (SD 71.0)
photons/s/cm2/sr. The tumour-to-tissue background ratio is 2.44.
Phosphorescent signals from the pathology inks used to orientate the
specimen prior to incision are also present (open arrows). The
posterior margin (blue) and superior margin (green) are visible; both
margins were clear (C5 mm) on CLI and histopathology, respectively
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accurate depiction of the location and extent of the tumour,
thereby aiding the surgeon in more accurate tumour
excision.
Conclusions
CLI is a fast-emerging optical imaging technology that
has rapidly progressed from bench to bedside. This rapid
development has been facilitated by the ability to use
clinically approved tumour-targeted PET tracers. Due to
its high-resolution, wide applicability across a range of
solid cancers and small size imaging equipment, CLI is
of particular interest in the field of image-guided sur-
gery. Challenges for the clinical implementation of this
technique include the low signal intensity, the require-
ment for light-tightness, the minute-scale image acqui-
sition times and the logistical issues associated with
using radiotracers intraoperatively. Preclinical studies
have shown that CLI can be successfully used to guide
surgical resection of tumours and lymph nodes, as well
as to detect cancerous lesions using Cerenkov lumines-
cence endoscopy. Several clinical studies on the preop-
erative and intraoperative use of CLI in breast cancer,
prostate cancer, gastrointestinal cancer and metastatic
lymph nodes are currently underway. Results from these
studies, together with ongoing developments in ultra-
sensitive camera technology will help drive widespread
clinical adoption. By improving the accuracy of surgical
resections, CLI has the potential to become a disruptive
technology in cancer surgery.
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